LFM-A13 is primarily used in biochemical and pharmacological research as a selective inhibitor of Bruton's tyrosine kinase (BTK). It is employed to study signaling pathways in B-cell lymphomas and other hematological cancers. Researchers use LFM-A13 to investigate the role of BTK in cell proliferation, survival, and apoptosis, particularly in malignant B cells. Due to its ability to induce apoptosis in certain cancer cell lines without affecting normal lymphocytes significantly, it serves as a tool compound in developing targeted cancer therapies. It has also been explored in studies related to autoimmune diseases where B-cell signaling plays a critical role.